Abstract 1588P
Background
HZ infection is a potential cause of additional morbidity in immunocompromised patients (pts). ASCO, ESMO, and AIOM recommend recombinant zoster vaccine (RZV, Shingrix®, GSK) for pts who are immunocompromised due to cancer therapy. Vaccination rates among these pts remain suboptimal, and research on effective interventions to improve vaccination rates is limited. We report quality improvement interventions aimed at enhancing vaccine uptake among cancer outpatients.
Methods
A two-phase vaccination program for cancer outpatients receiving cancer treatments attending the Medical Oncology department of ASST Rhodense was conducted. Firstly, based on previous COVID-19 experience and with the collaboration of pts asociation La Lampada di Aladino ETS, a cross-sectional survey was administered to evaluate knowledge and awareness about HZ and RZV, vaccine hesitancy and the willingness of oncology pts to receive the RZV directly in the oncology department. Subsequently, an in-house vaccination program was managed by oncology staff.
Results
Two hundred pts conducted the survey while undergoing cancer treatment, highlighting partial understanding of HZ and RZV and a huge willingness to receive RZV from oncological staff. From June 2023 to April 2024, 220 pts received at least 1 dose of RZV, among which 152 (69%) received the second dose, resulting in a vaccination rate of 44% (220/496). Pts characteristics were as follows: 57% female, median age 70 (43-93) years, 80% ECOG PS 0-1, and 39% with at least 3 comorbidities. The most frequent tumors were breast 29%, lung 18%, colorectal 14%, prostate 10%, and upper GI 6%. The most common anticancer treatments were chemotherapy 44%, immunotherapy 28% targeted therapy 23%, and endocrine therapy 5%. No severe adverse event to RZV were reported. RZV was administered on average 7 (0-51) days before and 8 (0-70) days after intravenous therapy respectively.
Conclusions
Most cancer pts have a limited perception of the importance of vaccination. Vaccination with RZV was found to be safe. Our study highlights the potential for in-hospital vaccination strategies to enhance vaccination coverage and improve health outcomes among oncology pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
GSK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10